Expand Document | Expand Chapter | Full TOC | Printable HTML version
Scaling up Antiretroviral Therapy in Resource Limited Settings : Guidelines for a Public Health Approach
(2002; 163 pages) [French] View the PDF document
Table of Contents
View the documentAbbreviations
View the documentPreface
View the documentSummary
View the documentI. Introduction
View the documentII. Objectives of the document
View the documentIII. Background and purpose
View the documentIV. Approach to antiretroviral therapy
View the documentV. When to start antiretroviral therapy in adults and adolescents
View the documentVI. Recommended first-line regimens for adults and adolescents
View the documentVII. When to change therapy in adults and adolescents
View the documentVIII. Recommended second-line regimens in adults and adolescents
View the documentIX. Drug resistance
View the documentX. Antiretroviral therapy in women, with specific reference to pregnancy
View the documentXI. Infants and children
View the documentXII. Tuberculosis and other HIV-related conditions
View the documentXIII. Injecting drug users
View the documentXIV. Drug adherence
Open this folder and view contentsXV. Monitoring antiretroviral therapy
View the documentReferences
View the documentInterim WHO Antiretroviral Treatment Working Group, Geneva, 19-20 november 2001
View the documentWHO International Consultative Meeting on HIV/AIDS Antiretroviral Therapy, 22-23 May 2001, Geneva
 

Preface

Less than a decade ago, someone living with HIV/AIDS had little hope.HIV infection brought a steady inexorable decline towards the complete destruction of the immune system and death. The introduction of ARVs in 1996 was a turning point for hundreds of thousands of people with access to sophisticated health care systems. Although they cannot cure HIV/AIDS, antiretrovirals (ARVs) have dramatically reduced mortality and morbidity, prolonged lives, and improved the quality of life of many people living with HIV/AIDS.

Today we are once again at a turning point - this time in favour of the developing world. Thanks to the work of hundreds of individuals and activists in NGOs, governments, UN agencies and the private sector, prices of ARVs have fallen and we are now in a position to consider scaling up access in resource limited settings.

Scaling up will not be possible in the absence of a clear public health approach that promotes the rational and safe use of these powerful and precious medicines. These technical guidelines, developed with the support of the US National Institutes of Health, present such an approach, promoting the use of standardized regimens and simplified monitoring. They recommend standards for the large-scale introduction of ARVs that prevent misuse. This is essential for good patient adherence and correct use by prescribers.

WHO estimates that in 2002, some 6 million people in developing countries are in need of life-sustaining ARV therapy now. Instead, only 230,000 have such access today, and half of these live in one country, Brazil. We believe that the countries of the developing world should be able to have 3 million people on ARVs by the end of 2005 – provided that the world follows through on the international concerted effort to expand access to HIV treatment and care. This ten-fold increase matters for many reasons. Three million people will be granted a new lease on life, wider access to treatment will stimulate prevention and there will be positive impacts on social and economic development as people living with HIV live longer and more productive lives.

These guidelines offer a chance of hope to those who despaired. They affirm the human rights and dignity of people living with HIV. They represent an opportunity to build upon the solidarity and energy of the global movement against HIV/AIDS by redressing the inequities between rich and poor in access to care. They will be updated on a regular basis as new information and evidence becomes available. As we look to the future, WHO will continue to work with its partners around the world to further increase access to care and support to all who need it.

Tomris Türmen

Executive Director
Family and Community Health
World Health Organization
Geneva
April 2002

to previous section to next section
 

Last updated: May 3, 2013